Nonprofit models support strategic boldness to develop gene therapies for rare diseases [Yahoo! Finance]
Novartis AG (NVS)
Last novartis ag earnings: 4/28 01:00 am
Check Earnings Report
US:NYSE Investor Relations:
novartis.com/investors
Company Research
Source: Yahoo! Finance
Gene therapies represent a fundamental approach to tackling the root cause of many rare diseases, since roughly 80% are genetic. While cell and gene therapies (CGTs) have faced a challenging investor environment in recent years, nonprofit organisations can offer a lifeline to the longevity of the sector. One such example is the Italian non-profit organisation Fondazione Telethon (FT), which developed the first gene therapy to gain approval in Wiskott-Aldrich Syndrome. To provide access to treatment in a sustainable way, FT will commercialise the therapy to generate revenue that can be reinvested in the company. FT is not the only non-profit in Europe with its sights set on bringing gene therapies to patients with a rare disease. French R&D company Généthon is investigating 12 gene therapies in clinical trials across neuromuscular, blood and metabolic disorders. The nonprofit also specialises in developing new vector technologies; optimising bioproduction methods for cost reduction
Show less
Read more
Impact Snapshot
Event Time:
NVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVS alerts
High impacting Novartis AG news events
Weekly update
A roundup of the hottest topics
NVS
News
- Novartis AGM Links Board Refresh And Dividend Growth To Future Returns [Yahoo! Finance]Yahoo! Finance
- Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa [Yahoo! Finance]Yahoo! Finance
- Peanut Allergy Market Analysis Report 2025-2035: PALFORZIA and Xolair Approvals, Improved Diagnosis and Innovative Drug Delivery Platforms Drive Growth [Yahoo! Finance]Yahoo! Finance
- Lilly unveils $3 billion production expansion in China [Yahoo! Finance]Yahoo! Finance
- Novartis (NVS) was upgraded by Argus from "hold" to "buy". They now have a $180.00 price target on the stock.MarketBeat
NVS
Earnings
- 2/4/26 - Beat
NVS
Sec Filings
- 2/12/26 - Form 144
- 2/9/26 - Form 144
- 2/4/26 - Form S-8
- NVS's page on the SEC website